215 related articles for article (PubMed ID: 27183455)
1. A contemporary cross-sectional study on dyslipidemia management, cardiovascular risk status, and patients' quality of life in Greece: The CHALLENGE study.
Alexopoulos D; Anastasiou-Nana M; Elisaf MS; Liberopoulos E; Rallidis LS; Davos CH; Moulis A; Nikas N; Zacharis E; Vardas P;
Int J Cardiol; 2016 Aug; 217():183-9. PubMed ID: 27183455
[TBL] [Abstract][Full Text] [Related]
2. Lipid target achievement among patients with very high and high cardiovascular risk in a lipid clinic.
Barkas F; Liberopoulos EN; Kostapanos MS; Liamis G; Tziallas D; Elisaf M
Angiology; 2015 Apr; 66(4):346-53. PubMed ID: 24830420
[TBL] [Abstract][Full Text] [Related]
3. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
Van Ganse E; Laforest L; Burke T; Phatak H; Souchet T
Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548
[TBL] [Abstract][Full Text] [Related]
4. Attainment of low-density lipoprotein cholesterol target in the French general population according to levels of cardiovascular risk: Insights from the MONA LISA study.
Bongard V; Dallongeville J; Arveiler D; Ruidavets JB; Amouyel P; Wagner A; Ferrières J
Arch Cardiovasc Dis; 2013 Feb; 106(2):93-102. PubMed ID: 23527913
[TBL] [Abstract][Full Text] [Related]
5. Achievement of LDL-C Targets Defined by ESC/EAS (2011) Guidelines in Risk-Stratified Korean Patients with Dyslipidemia Receiving Lipid-Modifying Treatments.
Yang YS; Lee SY; Kim JS; Choi KM; Lee KW; Lee SC; Cho JR; Oh SJ; Kim JH; Choi SH
Endocrinol Metab (Seoul); 2020 Jun; 35(2):367-376. PubMed ID: 32615721
[TBL] [Abstract][Full Text] [Related]
6. [Status of cholesterol goal attainment for the primary and secondary prevention of atherosclerotic cardiovascular disease in dyslipidemia patients receiving lipid-lowering therapy: DYSIS-China subgroup analysis].
Li Y; Zhao SP; Ye P; Yan XW; Mu YM; Wei YD; Hu DY;
Zhonghua Xin Xue Guan Bing Za Zhi; 2016 Aug; 44(8):665-70. PubMed ID: 27545124
[TBL] [Abstract][Full Text] [Related]
7. Management of low-density lipoprotein cholesterol levels in South Africa: the International ChoLesterol management Practice Study (ICLPS).
Blom DJ; Raal F; Amod A; Naidoo P; Lai YE;
Cardiovasc J Afr; 2019 Jan/Feb 23; 30(1):15-23. PubMed ID: 30720848
[TBL] [Abstract][Full Text] [Related]
8. Low-density lipoprotein cholesterol in a global cohort of 57,885 statin-treated patients.
Gitt AK; Lautsch D; Ferrieres J; Kastelein J; Drexel H; Horack M; Brudi P; Vanneste B; Bramlage P; Chazelle F; Sazonov V; Ambegaonkar B
Atherosclerosis; 2016 Dec; 255():200-209. PubMed ID: 27667299
[TBL] [Abstract][Full Text] [Related]
9. Vascular risk factors, vascular disease, lipids and lipid targets in patients with familial dysbetalipoproteinemia: a European cross-sectional study.
Koopal C; Retterstøl K; Sjouke B; Hovingh GK; Ros E; de Graaf J; Dullaart RP; Bertolini S; Visseren FL
Atherosclerosis; 2015 May; 240(1):90-7. PubMed ID: 25768710
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Low-density Lipoprotein Cholesterol Target Attainment Rates According to the 2016 and 2019 European Society of Cardiology/European Atherosclerosis Society Dyslipidemia Guidelines for Secondary Prevention in Patients with Acute Myocardial Infarction.
Şimşek B; İnan D; Çınar T; Cagdas-Yumurtaş A; Ozan-Tanık V; Zeren G; İlker-Avcı İ; Yücel-Karabay C; Güngör B; Tokgozoğlu L
Rev Invest Clin; 2021 Nov; 73(3):371-378. PubMed ID: 34098569
[TBL] [Abstract][Full Text] [Related]
11. The control of dyslipidemia in outpatient clinics in Greece (OLYMPIC) Study.
Diamantopoulos EJ; Athyros VG; Yfanti GK; Migdalis EN; Elisaf M; Vardas PE; Manolis AS; Karamitsos DT; Ganotakis ES; Hatseras D;
Angiology; 2005; 56(6):731-41. PubMed ID: 16327950
[TBL] [Abstract][Full Text] [Related]
12. Cholesterol goal attainment in hypertensive patients: the impact of metabolic syndrome components.
Rodrigues CJ; Ribeiro HF; Ribeiro AB; Zanella MT; Batista MC
Metab Syndr Relat Disord; 2012 Jun; 10(3):195-201. PubMed ID: 22313142
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study.
Halcox JP; Banegas JR; Roy C; Dallongeville J; De Backer G; Guallar E; Perk J; Hajage D; Henriksson KM; Borghi C
BMC Cardiovasc Disord; 2017 Jun; 17(1):160. PubMed ID: 28623902
[TBL] [Abstract][Full Text] [Related]
14. Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada.
Gitt AK; Drexel H; Feely J; Ferrières J; Gonzalez-Juanatey JR; Thomsen KK; Leiter LA; Lundman P; da Silva PM; Pedersen T; Wood D; Jünger C; Dellea PS; Sazonov V; Chazelle F; Kastelein JJ;
Eur J Prev Cardiol; 2012 Apr; 19(2):221-30. PubMed ID: 21450578
[TBL] [Abstract][Full Text] [Related]
15. Achieving low-density lipoprotein cholesterol treatment goals among dyslipidemic individuals in the Levant: the CEntralized Pan-Levant survey on tHE Undertreatment of hypercholeSterolemia (CEPHEUS) study.
Hammoudeh AJ; Echtay A; Ghanem GY; Haddad J;
Curr Med Res Opin; 2014 Oct; 30(10):1957-65. PubMed ID: 24889279
[TBL] [Abstract][Full Text] [Related]
16. Current cardiovascular risk management patterns with special focus on lipid lowering in daily practice in Switzerland.
Jaussi A; Noll G; Meier B; Darioli R
Eur J Cardiovasc Prev Rehabil; 2010 Jun; 17(3):363-72. PubMed ID: 20168234
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of dyslipidaemia in patients treated with lipid-lowering agents in China: results of the DYSlipidemia International Study (DYSIS).
Zhao S; Wang Y; Mu Y; Yu B; Ye P; Yan X; Li Z; Wei Y; Ambegaonakr BM; Hu D;
Atherosclerosis; 2014 Aug; 235(2):463-9. PubMed ID: 24950001
[TBL] [Abstract][Full Text] [Related]
18. Lipid-lowering therapy and risk-based LDL-C goal attainment in Belgium: DA VINCI observational study.
van de Borne P; Peeters A; Janssens L; Leone A; Lemmens R; Verhaegen A; De Meulemeester M; Balthazar Y; Heijmans S; Calozet Y; Paquot N; Carlier S; Hemelsoet D; Bray S; Ray KK
Acta Cardiol; 2024 Feb; 79(1):20-29. PubMed ID: 35442151
[TBL] [Abstract][Full Text] [Related]
19. Prevalence and risk distribution of residual dyslipidemia in statin-treated patients in Greece.
Liberopoulos E; Vlasserou F; Mitrogianni Z; Papageorgantas I; Elisaf M;
Angiology; 2012 Apr; 63(3):184-93. PubMed ID: 21676964
[TBL] [Abstract][Full Text] [Related]
20. Long-term achievement of the therapeutic objectives of lipid-lowering agents in primary prevention patients and cardiovascular outcomes: an observational study.
Van Ganse E; Souchet T; Laforest L; Moulin P; Bertrand M; Le Jeunne P; Chretin S; Yin D; Alemao E; de Pouvourville G
Atherosclerosis; 2006 Mar; 185(1):58-64. PubMed ID: 16038912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
